| Nov 6 |
Surrozen to Present at Upcoming Healthcare Investor Conferences
|
| Nov 6 |
Surrozen GAAP EPS of -$0.44
|
| Nov 6 |
Surrozen Provides Third Quarter 2024 Financial Results and Business Update
|
| Sep 24 |
Surrozen earns $10M milestone payment through Boehringer collaboration
|
| Sep 24 |
Surrozen Earns $10 Million Milestone Payment in Retinal Diseases Collaboration
|
| Aug 15 |
Companies Like Surrozen (NASDAQ:SRZN) Could Be Quite Risky
|
| Aug 13 |
Surrozen GAAP EPS of -$7.99
|
| Aug 12 |
Surrozen Provides Second Quarter 2024 Financial Results and Business Update
|
| Jun 12 |
Surrozen Publishes Study in ‘eLife’ Demonstrating the Promise of The Proprietary SWEETS Platform, a Unique Targeted Protein Degradation Technology, to Further Enhance Wnt Signaling
|
| Jun 10 |
Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver (EASL) in Milan
|
